(Press-News.org) A recent clinical trial found that the adult antiviral drug, tenofovir disoproxil fumarate (tenofovir DF), is safe and effective in treating adolescents with hepatitis B virus (HBV). Trial results published in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases (AASLD), show that tenofovir DF suppressed HBV in 89% of pediatric participants.
Chronic HBV is a major health burden that studies estimate affects 350 million people worldwide, with 600,000 deaths attributed to this chronic disease. The Centers for Disease Control and Prevention (CDC) estimate that more than one million Americans have chronic HBV, with most patients infected during childhood. Medical evidence suggests that 90% of patients infected as infants, and up to 50% infected between one and four years of age develop chronic HBV; 25% of adults who become chronically infected in childhood develop cirrhosis or liver cancer.
"Children chronically infected with HBV are at great risk of developing severe liver disease and possible death due to complications from the disease," said Dr. Karen Murray, Chief of the Division of Gastroenterology and Hepatology at Seattle Children's Hospital in Washington and lead researcher of the clinical trial. "Tenofovir DF is highly effective in treating adults with chronic HBV and our trial evaluated safety and efficacy of the drug in adolescents."
This double-blind, placebo-controlled trial was conducted in 101 adolescents aged 12 to 17 years. Participants were randomized with 52 receiving a daily 300 mg dose of tenofovir DF and 54 taking a placebo for 72 weeks. A virologic response—ability of the antiviral medication to suppress the virus in participants—was the main outcome of this clinical trial. At the onset of the trial 91% of participants tested positive for the hepatitis B e-antigen and 85% received prior HBV therapy.
Researchers observed a virologic response in 89% of participants who received tenofovir DF, while none of the patients in the placebo group achieved HBV suppression. The drug successfully suppressed HBV and normalized alanine aminotransferase (ALT) levels in both adolescents who received no prior treatment and in those previously exposed to HBV therapy. No safety issues, such as a 6% reduction in spine bone density (safety end point), were reported. Trial participants taking tenofovir showed no resistance to the drug.
"Tenofovir DF therapy was well tolerated and effective in suppressing HBV in adolescents," concludes Dr. Murray. "Our trial demonstrates that tenofovir is a beneficial therapy for managing chronic HBV in teens." The authors note that a two-year open-label phase study will further investigate the sustained response and safety of tenofovir DF.
In an editorial also published in Hepatology, Dr. Philip Rosenthal with the University of California, San Francisco (UCSF) questions what can be done to alter the development of liver disease and liver cancer in children with chronic hepatitis B infection. "It was not long ago that drugs to treat HBV were limited and it is gratifying to see an increase in medications to combat this disease being approved for use in children and teens," said Dr. Rosenthal. "While the study by Murray et al. was limited to adolescents, future study of tenofovir DF in younger children is underway."
###
This study and editorial are published in Hepatology. Media wishing to receive a PDF of these articles may contact sciencenewsroom@wiley.com.
Full citation: "Randomized, Placebo-Controlled Trial of Tenofovir Disoproxil Fumarate in Adolescents with Chronic Hepatitis B." Karen F. Murray, Leszek Szenborn, Jacek Wysocki, Stephen Rossi, Amoreena C. Corsa, Phillip Dinh, John McHutchison, Phillip S. Pang, Luminita M. Luminos, Malgorzata Pawlowska and Jacek Mizerski. Hepatology; (DOI: 10.1002/hep.25818); Print Issue Date: December, 2012.URL: http://doi.wiley.com/10.1002/hep.25818
Editorial: Another Drug in the Armamentarium to Combat HBV in Adolescents." Philip Rosenthal. Hepatology; (DOI: 10.1002/hep.25901); Print Issue Date: December, 2012.URL: http://doi.wiley.com/10.1002/hep.25901
Author Contact: Media wishing to speak with Dr. Murray may contact Kathy Porada with Seattle Children's Hospital at kathy.porada@seattlechildrens.org or at 206-987-7856. To speak with Dr. Rosenthal, please contact Abigail Mortimore with the UCSF at abigail.mortimore@ucsf.edu or at 415-476-8810.
About the Journal
Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.
About Wiley
Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.
Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.
Researchers at Johns Hopkins Medicine in November surgically implanted a pacemaker-like device into the brain of a patient in the early stages of Alzheimer's disease, the first such operation in the United States. The device, which provides deep brain stimulation and has been used in thousands of people with Parkinson's disease, is seen as a possible means of boosting memory and reversing cognitive decline.
The surgery is part of a federally funded, multicenter clinical trial marking a new direction in clinical research designed to slow or halt the ravages of the disease, ...
New York, NY—December 5, 2012—Computer scientists at Columbia's School of Engineering and Applied Science have published a study in the November 2012 issue of The American Journal of Human Genetics (AJHG) that demonstrates a new approach used to analyze genetic data to learn more about the history of populations. The authors are the first to develop a method that can describe in detail events in recent history, over the past 2,000 years. They demonstrate this method in two populations, the Ashkenazi Jews and the Masai people of Kenya, who represent two kinds of histories ...
This press release is available in German.
Researchers of the KIT Institute of Functional Interfaces (IFG), Jacobs University Bremen, and other institutions have developed a new method to produce metal-organic frameworks (MOFs). By means of the so-called liquid-phase epitaxy, the scientists succeeded in producing a new class of MOFs with a pore size never reached before. These frameworks open up interesting applications in medicine, optics, and photonics. The new class of MOFs, called "SURMOF 2", is presented in the "Nature Scientific Reports" journal.
Metal-organic ...
BLOOMINGTON, Ind. -- At a Bloomington, Ind., toy store, kids ages 8 to 12 gather weekly to trade Pokemon cards and share their mutual absorption in the intrigue and adventure of Pokemon.
This may seem an unlikely source of material to test theories in cognitive neuroscience. But that is where Indiana University brain scientists Karin Harman James and Tom James were when an idea took hold.
"We were down at the club with our son, watching the way the kids talked about the cards, and noticed it was bigger than just a trading game," Tom James said.
Pokemon has since ...
PHILADELPHIA — Roughly one-fifth of Americans take low-dose aspirin every day for heart-healthy benefits. But, based on either urine or blood tests of how aspirin blocks the stickiness of platelets – blood cells that clump together in the first stages of forming harmful clots – up to one third of patients are deemed unlikely to benefit from daily use. Such patients are called "aspirin resistant." Clots are the main cause of most heart attacks and strokes.
In people who have suffered a heart attack, low-dose aspirin reduces the chances of a second event by about one fifth, ...
PROVIDENCE, R.I. – If you're thinking that little old lady driving 35 miles per hour in the passing lane shouldn't be behind the wheel, you may be right. Studies at Rhode Island Hospital, and elsewhere, have shown that our driving abilities decline with age, and for those with cognitive issues such as dementia, it can be even worse.
A standardized road test – much like the one teenagers take to receive their learner's permit and driver's license – is often used to measure an individual's performance, including those of older adults. But researchers at the Rhode Island ...
GAINESVILLE, Fla. — A new study co-authored by a University of Florida researcher provides the first direct chronological test of sequence stratigraphy, a powerful tool for exploring Earth's natural resources.
The model allows geologists to better understand how sedimentary rocks are related to one another in time and space and predict what types of rocks are located in different areas. The information may help scientists more reliably interpret various aspects of Earth's history such as long-term climate changes or extinction events, and also benefit companies searching ...
University of Rochester Medical Center scientists are testing a new approach to speed a patient's recovery of blood counts during a vulnerable period after a stem-cell transplant, according to a study published in the journal Stem Cells.
Laura M. Calvi, M.D., and Rebecca L. Porter, an M.D./Ph.D. student in Calvi's lab, reported that prostaglandin E2 (PGE2), a drug previously used to treat stomach ulcers, boosts blood production following an assault on the bone marrow from radiation or chemotherapy. Although their study was done in mice, Calvi believes it has significance ...
A new study finds differences in the ways that participation in Alcoholics Anonymous (AA) helps men and women maintain sobriety. Two Massachusetts General Hospital (MGH) investigators found that, while many factors are helpful to all AA participants, some were stronger in men and some in women. For example, avoidance of companions who encourage drinking and social situations in which drinking is common had more powerful benefits for men, while increased confidence in the ability to avoid drinking while feeling sad, depressed or anxious appeared to be more important for ...
VIDEO:
New research from Western University could lead to better treatments for Post-Traumatic Stress Disorder (PTSD) and drug addiction by effectively blocking memories. Steven Laviolette and Nicole Lauzon describe how...
Click here for more information.
New research from Western University could lead to better treatments for Post-Traumatic Stress Disorder (PTSD) and drug addiction by effectively blocking memories. The research performed by Nicole Lauzon, a PhD candidate ...
